legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Lexeo Therapeutics Expands Leadership Team Amid Breakthroughs in Cardiovascular Medicine

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a pioneering clinical-stage genetic medicine firm committed to developing groundbreaking treatments for cardiovascular diseases, has announced several key senior leadership appointments. This strategic move highlights the company’s deepening expertise in the realm of cardiovascular medicine and its continued advancements in late-stage clinical development. Alongside this, Lexeo provided an update on its strategic partnership formed in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners. This collaboration focuses on developing therapies for genetic cardiac diseases using a novel non-viral RNA delivery platform, which presents promising opportunities for innovation in this critical health sector.

Strategic Leadership Changes

Appointment of Dr. Narinder Bhalla as Chief Medical Officer

In an important step forward, Dr. Narinder Bhalla, MD, has been appointed as Chief Medical Officer, effective immediately. Dr. Bhalla brings more than two decades of rich experience as an interventional cardiologist, alongside nearly ten years in leadership roles within the biopharma sector. His extensive background includes prominent positions at AstraZeneca and Bristol Myers Squibb, where he served as Senior Vice President and Head of Global Medical in Immunology and Cardiovascular sectors. Renowned for his ability to build and scale impactful medical and clinical development organizations, Dr. Bhalla’s leadership skills have been crucial in executing successful global product launches that achieve significant health outcomes for patients.

Transition for Dr. Eric Adler to CEO of Myoventive

In tandem with Dr. Bhalla’s appointment, Dr. Eric Adler, MD, who is currently the Head of Research at Lexeo Therapeutics, will now serve as President and Chief Executive Officer at Myoventive, Inc. This cardiac precision medicines company, co-founded by Lexeo in June 2025 in partnership with Perceptive Xontogeny Venture Funds and venBio Partners, focuses on targeted RNA modulation to tackle genetic cardiac diseases that are not adequately addressed by existing AAV platforms. Dr. Adler’s continuous role as a senior clinical and scientific advisor to Lexeo ensures his expertise remains integral to the company’s innovations.

Leadership Comments

Expressing his enthusiasm for the advancements ahead, R. Nolan Townsend, CEO of Lexeo Therapeutics, stated, “As we advance the development of LX2006 and prepare for the next phases of Lexeo’s growth, Dr. Bhalla’s robust global medical leadership, proven commercial launch experience, and in-depth cardiovascular expertise will enable us to transform our scientific potential into tangible impact for patients.” He further emphasized the collaborative nature of these appointments, which will fortify the company’s capacity to meet both late-stage clinical and commercial objectives while continuing to invest heavily in early cardiac development.

Reinforcing Commitment to Cardiovascular Health

Dr. Bhalla’s Vision

“I feel deeply honored to join Lexeo at such a crucial juncture,” said Dr. Bhalla. “The mission to revolutionize the treatment of genetically mediated cardiovascular diseases resonates with my own professional aspirations, aiming to address significant unmet medical needs. I am excited to collaborate with this accomplished team to drive forward the development of LX2006 and our broader pipeline, focused intensely on patient outcomes.”

Additional Leadership Appointments

Alongside Dr. Bhalla, Lexeo announced several other key appointments:

• José Manuel Otero, PhD has been appointed as Chief Operating Officer from his prior role as Chief Technical Officer. Dr. Otero’s leadership was instrumental in achieving industry-leading cost efficiencies and navigating significant manufacturing transitions while ensuring regulatory compliance.

• Hayes Dansky, MD joins as Vice President of Late-Stage Cardiology Development. With two decades of clinical research experience, he brings extensive expertise from past roles in leading cardiovascular studies and initiatives aimed at cardiometabolic diseases.

• Greg Aubert, MD, PhD is stepping into the role of Vice President for Early-Stage Cardiology Development and Translational Science. His background in cardiovascular genetics and gene therapy will significantly boost Lexeo’s research initiatives.

The Role of AI legalese decoder

As Lexeo Therapeutics forges new paths in cardiovascular treatments through innovative therapies and strategic partnerships, navigating the complexities of medical and regulatory documentation is crucial. This is where AI legalese decoder can make a significant impact. By simplifying intricate legal language related to clinical trials, partnerships, and regulatory compliance into more digestible formats, it empowers companies like Lexeo to ensure clarity and transparency. This technology mitigates risks associated with misinterpretations in legal documents and enables teams to focus on their core mission—developing transformative treatments for patients suffering from cardiac diseases.

About Lexeo Therapeutics

Lexeo Therapeutics is a New York-based clinical-stage genetic medicine company dedicated to redefining heart health by leveraging cutting-edge science to change treatment paradigms in cardiovascular diseases. The company is advancing a portfolio of therapeutic candidates aimed at the genetic roots of various ailments, including LX2006 for Friedreich ataxia (FA) cardiomyopathy and LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, addressing critical unmet needs in healthcare.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" under federal securities laws. These statements reflect Lexeo’s expectations regarding current product candidates and their potential benefits. Lexeo urges caution against relying solely on these statements, as they depend on various factors that could lead to differing actual results, including unexpectedly prolonged study timelines, regulatory approval delays, and other unforeseen challenges.

For further inquiries:

Media Response

Media: [email protected]

Investor Response

Ashley Kaplowitz
[email protected]

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link